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van Leeuwen's Response
In our paper, "Toxic Equivalency Factors
(TEFs) for PCBs, PCDDs, PCDFs for
Humans and Wildlife" (1), we described the
results of a World Health Organization
(WHO) working group that evaluated the
existing TEFs for human risk assessment and
derived consensus TEFs for fish and birds.
Starr et al. comment on the approach
taken for the derivation of TEFs as
described in our paper (1) and criticize the
inadequate characterization of the uncer-
tainty ofthe TEFs. They state that the fol-
lowing sentence is the only uncertainty
characterization:
... it is unlikely for the use ofthis additive model
to result in a great deal oferror in predicting the
concentrations of TCDD TEQs or responses at
environmentally relevant levels due to nonaddi-
tive interactions.
In addition, they request explicit quantita-
tive estimates on the uncertainty in each
REP value, each TEF, and on the deviation
from parallelism for the different end points.
Their first statement is incorrect. In the
paper we clearly stated that the TEFs that
were derived are "an order of magnitude
estimate." This is a clear illustration of the
overall uncertainty in TEF values based on
the differences in outcomes ofthe different
end points and the variation in available
data for the different congeners. In addi-
tion, Starr et al. misinterpreted the sentence
quoted above. This sentence is based on the
opinion ofVan den Berg et al. (1) that the
use of an additive model in the TEF
approach, in contrast to including nonad-
ditive (synergistic or antagonistic) effects,
does not result "in a great deal oferror."
Providing a quantitative estimate of the
uncertainty of the individual REPs, as
requested by Starr et al., is often not possible.
Uncertainty in no-observed-(adverse)-effect
levels [or lowest-observed-(adverse)-effect lev-
els] or EC50 is usually not given in the stud-
ies used by the WHO working group.
Therefore, a more qualitative, tiered
approach was chosen to select the REPvalues
in which we had greatest confidence, and not
because we believe they are "without error."
This weighted procedure is clearly outlined
in the original paper. For those scientists who
want to address the variation in REP values
in more detail, the database containing all the
information that was used in the derivation
ofTEFs is available on request. In their com-
ments, Starr et al. suggestively stated that
"the database is said to be available." The
database was available directly after the
WHO TEF meeting that was held in June
1997. Requests were received from several
people, and all ofthem received the data.
Regarding their comment on the
requirement of "parallelism of dose-
response curves across end points" Starr et
al. apparently failed to understand that the
cascade of events following binding to the
Ah receptor is different for each end point,
which might thus result in different
dose-response curves. Basic pharmacology
and endocrinology have shown that multi-
ple responses mediated by the same recep-
tor mechanism do not have to have parallel
dose-response curves because binding to a
receptor is but the first step in the cascade
of responses. Thus, per definition, the
dose-response curves for different health
end points cannot be expected to be paral-
lel. This is one of the inherent uncertain-
ties in the derivation of TEFs, but this is
well recognized and covered adequately by
Van den Berg et al. (1). Parallel
dose-response curves are required for dif-
ferent congeners examining the same
response, but this has been amply demon-
strated in the literature for various dioxins,
furans, and PCBs for various responses,
and it was adequately covered by Van den
Berg et al.
Where Starr et al. criticize the current
approach and advocate the derivation of
"species-, end point-, and dose-specific
TEFs," it should be mentioned that the
lack of information on dose-response rela-
tionships for all congeners, all end points/
responses, and all species was just one of
the reasons to develop the TEF methodolo-
gy. It is highly unlikely that we could test
all the congeners for all relevant end points
and all species, including humans.
Finally, the TEF approach is a risk
assessment tool; it was not developed to
produce precise estimates of risk, but to
approximate the toxic potency ofexposure
to a mixture ofdioxin-like compounds. As
such, it appears to work remarkably well. A
large number ofstudies published in peer-
reviewed literature have demonstrated a
statistically highly significant correlation
between TEQ levels in complex mixtures,
derived by making use of TEFs, and pre-
dicted health outcomes in different animal
species. An overview of this can be found
in a series of articles in Human and
Ecological Risk Assessment, Volume 5
(1999), in which several of these studies
have been cited. Thus, we conclude that
although the TEF approach might not be
perfect because of its inherent uncertain-
ties, no valid alternative for risk assessment
purposes currently exists.
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Safe Food: Should We Be
Afraid?
I would like to comment on the article
"Safe Food: An All-consuming Issue" (1). I
consider this article to be scaremongering.
Scaremongering, a very real and increasingly
dangerous problem, often with total disre-
gard to the truth, has become a major, and
obviously profitable, growth industry
wherein "nonprofit" organizations and vari-
ous individuals prosper at the expense ofthe
credulous public. Just how credulous can
the public be? This week I had a vivid
example when my wife of 55 years, on the
basis of a recent article, told me she would
no longer serve me meat products such as
salami and summer sausage, which I have
been happily consuming for most ofmy life!
True, meat contamination by such
organisms as Salmonella and new virulent
mutant strains of Escherichia coli kills many
people every year, usually in fresh ground
meat. These deaths are totally avoidable by
the appropriate use of irradiation. I have
worked with or studied food irradiation since
1950 and know that, worldwide, hundreds
ofinvestigations have shown food irradiation
to be totallyeffective andcompletelysafe.
Yet Schmidt cites Food and Water mere-
ly as a "nonprofit advocacy organization."
How could he! This is the organization that
spends quite extraordinary amounts of
money proclaiming that anyone who eats
irradiated foods is likely to have severely
deformed children (among other horrors).
I could fill many pages with accounts of
encounters with some these dangerous
frauds, and over the years I have written
several articles on the topic ofscaremonger-
ing in the food industry (2-4).
I am old (81) and long retired (since
1982), and I profoundly hope that some-
time soon a publication such as EHP will
give the same concern to this scandal as you
would to any other virulent epidemic.
Thank you for this chance to blow off
some steam.
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DNA-Protein Cross-Links as a
Biomarker of Cr(VI) Exposure
We would like to provide some observations
regarding a paper by Zhitkovich et al. (1)
that appeared in EHP Supplements. In this
paper, the authors summarized theirfindings
to date regarding the possible use of
DNA-protein cross-links (DPC) in lympho-
cytes as a biomarker for human exposure to
hexavalent chromium [Cr(VI)]. We believe
that the research ofZhitkovich et al. (1) in
this area is timelyandpossibly ofgreat bene-
fit. Exposure to Cr(VI) in theworkplace and
the environment is clearly an increasing con-
cern on the part of many regulatory agen-
cies; for example, both the Occupational
Safety and Health Administration (OSHA)
and the U.S. Environmental Protection
Agency (EPA) have decided to reevaluate
longstanding Cr(VI) inhalation exposure
standards [the permissible exposure limit
(PEL) and the cancer slope factor]. Also, as
Zhitkovich et al. (1) noted, Cr(VI) is pre-
sent at elevated concentrations in soils and
groundwater at numerous locations in the
United States and elsewhere. However, as
of yet, there does not appear to be a suffi-
ciently reliable technique for biomonitoring
ofCr(VI) exposure. The limitations associ-
ated with urine chromium monitoring have
been discussed in the literature (2), and
hair, nail, and other tissue samples do not
provide a measure of exposure as they do
for other metals. Therefore, development of
a reliable biomarker for low-to-moderate
levels of exposure to Cr(VI) would have
obvious applications in occupational and
environmental settings.
We have preliminarily investigated the
usefulness of a variety of DNA effects as
possible markers of Cr(VI) exposure,
including the DPC lymphocyte assay (3).
Some ofthis work was done in conjunction
with Zhitkovich and his colleagues (4). Our
review of the recent paper by Zhitkovich et
al. (1) and the related manuscripts that have
appeared over the past 10 years suggests that
certain elements regarding the specificity
and sensitivity of the DPC assay have not
been consistently addressed in the literature,
and this has possibly lead to some confusing
and contradictory conclusions regarding the
potential utility of this biomarker. We
would like to take this opportunity to clarify
some of these issues and thereby focus
future research efforts on reducing the
uncertainties associated with this assay.
It is important to note that a causal rela-
tionship between human exposure to Cr(VI)
and increased lymphocyte DPC levels has
not yet been established. In the only pub-
lished study that measured DPC levels in cir-
culating human lymphocytes after exposure
to known doses of Cr(VI), we found that
ingestion of water containing 10 ppm
Cr(VI), which is 100 times the drinking
water standard (0.10 ppm), did not yield an
increase in DPC levels above predosing
"background" levels (5). This is in spite of
the fact that blood and urinary chromium
levels demonstrated that asubstantial fraction
of ingested chromium had been absorbed
[this study was not cited by Zhitkovich et al.
(1)]. Furthermore, in the only occupational
DPC studywhere there was clear evidence of
chromium exposure (chrome platers with
highly elevated blood chromium levels), lym-
phocyte DPC levels were no greater than in
the control group (6). In the other occupa-
tional and environmental Cr(VI) DPC stud-
ies (7-10), all ofwhich reported increased
DPC in the exposed population, chromium
body burdens were measured in the exposed
group only (8-J1), orwere measured in both
the exposed and control groups and found to
be the same (2). In short, no investigator has
yet identified a chromium-exposed popula-
tion that has shown both an increase in lym-
phocyte DPC levels and a chromium body
burden relative to a contemporaneously sam-
pledcontrol group.
The animal data are also inconclusive.
For example, lymphocyte DPC levels were
not increased in rats fed 100-200 ppm
Cr(VI) (1,000-2,000 times the drinking
water standard), even though tissue chromi-
um levels indicated that significant chromi-
um absorption had occurred (11). The in
vivo animal data that support a causal rela-
tionship reported a 2- to 4-fold increase in
lymphocyte DPC in rats injected intraperi-
toneally (ip) with 40 mg/kg chromate (12),
but even these results must be considered in
light of the fact that another investigator
using the same dosing regimen (but a differ-
ent cell preparation technique) showed no
increase in lymphocyte DPC (11).
Accordingly, we believe that additional (and
reproducible) in vivo animal exposure work
should be performed before it can be
concluded that relevant routes of Cr(VI)
exposure can in fact cause elevated lympho-
cyte DPC in an intact organism.
As noted above, increased lymphocyte
DPC levels in animals have been measured
only after ip administration of a Cr(VI)
dose (40 mg/kg chromate) that was highly
toxic if not lethal [the acute oral gavage
median lethal dose (LD50) for chromate
ranges from 13 to 28 mg/kg (13)].
Similarly, several researchers have suggested
that Cr(VI) will induce DPC in animal and
human cells in vitro only at cytotoxic con-
centrations (4). As described in the inter-
laboratory validation study (4),
For chromate, the number of crosslinks was not
increased at concentrations less than those that
caused an inhibition of cell proliferation and
which caused some degree of cell toxicity. At
higher concentrations, crosslinking was directly
related to the increase in long-term cytotoxicity.
Further, none ofthe occupational studies of
Cr(VI)-exposed workers have reported
more than a doubling ofbackground DPC
levels (6-9). The much lower environmen-
tal Cr(VI) exposures might not be sufficient
to induce DPC levels measurably above
those that normally exist. In short, as noted
by Costa et al. (4), it is unclear whether
DPC formation will prove to be sufficiently
sensitive to serve as a reliable biomarker for
most Cr(V1) exposures.
Zhitkovich et al. (1) indicated that their
DPC analysis "has been validated using var-
ious cross-linking agents in cultured cells."
Because we participated in the design and
interpretation of the DPC interlaboratory
validation study (4), we feel that some clari-
fication is appropriate. The study, which
involved five different laboratories testing
many different metal compounds, demon-
strated that while each lab obtained the
same qualitative results regarding which
metals induced DPC (copper, arsenic, and
chromium) and those which did not (mer-
cury, magnesium, permanganate, cadmium,
lead, and aluminum), the actual degree of
DPC measured in each lab was highly vari-
able. For example, the increase in DPC
induced by arsenic trioxide at 150 pm
ranged from 8- to 60-fold. Although several
possibilities for the interlaboratory variabili-
ty were discussed, we believe that it may be
premature to term the DPC assay as "vali-
dated"; we would encourage more research
into the reproducibility ofthe method.
There are some apparent contradictions
in the summary table presented by
Zhitkovich et al. (1); this table (Table 1)
contains the findings of the epidemiologic
studies that have examined DPC levels in
individuals thought to have experienced
Cr(VI) exposure. First, Zhitkovich et al. (1)
state that there were no confounders present
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